Wells Fargo raised the firm’s price target on Avidity Biosciences (RNA) to $75 from $70 and keeps an Overweight rating on the shares. The firm highlights RNA’s first- and best-in-class position for all three of its muscle disease programs and notes the string of regulatory filings and decisions starting in year-end 2025, which should drive further momentum for the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences: Promising Pipeline and Strong Financials Justify Buy Rating
- Avidity Biosciences: Strong Buy Rating Amidst Promising Muscle Disease Program Developments and Robust Financial Position
- Avidity Biosciences price target raised to $62 from $59 at Barclays
- Avidity Biosciences Signs Manufacturing Agreement with Lonza
- Avidity Biosciences reports Q2 EPS ($1.21), consensus (96c)